Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Clough Capital Partners L P

Key Points

• Clough Capital Partners L P decreased its position in Jazz Pharmaceuticals by 23.3% in Q1, now holding approximately 32,550 shares valued at $4.04 million.
• CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals, reducing his holdings by 0.23%, and now owns about 436,973 shares worth approximately $47 million.
• Jazz Pharmaceuticals reported a Q2 EPS of (8.25), missing estimates by ($2.64), while revenue remained steady at $1.05 billion compared to analyst expectations.

Clough Capital Partners L P decreased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 23.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 32,550 shares of the specialty pharmaceutical company's stock after selling 9,900 shares during the period. Clough Capital Partners L P owned approximately 0.05% of Jazz Pharmaceuticals worth $4,041,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Dimensional Fund Advisors LP boosted its stake in shares of Jazz Pharmaceuticals by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after buying an additional 293,360 shares during the period. Ameriprise Financial Inc. raised its holdings in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after purchasing an additional 315,608 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Jazz Pharmaceuticals by 4.7% during the first quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company's stock worth $206,343,000 after purchasing an additional 74,501 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in Jazz Pharmaceuticals by 41.7% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after purchasing an additional 391,660 shares in the last quarter. Finally, Vestal Point Capital LP raised its holdings in Jazz Pharmaceuticals by 8.3% during the fourth quarter. Vestal Point Capital LP now owns 975,000 shares of the specialty pharmaceutical company's stock worth $120,071,000 after purchasing an additional 75,000 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Up 1.5%

Shares of JAZZ traded up $1.91 during midday trading on Tuesday, hitting $129.66. The company had a trading volume of 863,918 shares, compared to its average volume of 950,014. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company's 50 day moving average price is $114.90 and its 200 day moving average price is $116.93. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The stock has a market cap of $7.87 billion, a price-to-earnings ratio of -19.27, a PEG ratio of 8.04 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the firm posted $5.30 earnings per share. The company's quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price objective for the company. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Finally, Morgan Stanley raised their target price on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research report on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $178.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.